Volume 28, Number 7—July 2022
Research Letter
University-Associated SARS-CoV-2 Omicron BA.2 Infections, Maricopa County, Arizona, USA, 2022
Nicole Fowle
, Brenna Garrett, O’Zandra L. Floyd, Jennifer Collins, Aaron D. Krasnow, Mario Islas, Steven C. Holland, Matthew F. Smith, Efrem S. Lim, Nicole M. Jarrett, and Sarah E. Scott
, Brenna Garrett, O’Zandra L. Floyd, Jennifer Collins, Aaron D. Krasnow, Mario Islas, Steven C. Holland, Matthew F. Smith, Efrem S. Lim, Nicole M. Jarrett, and Sarah E. Scott
Table
Characteristics of SARS-CoV-2 B.1.1.529 Omicron BA.2 cases among students and staff affiliated with a local university, Maricopa County, Arizona, USA, January 2022*
| Characteristics | No. (%) |
|---|---|
| Median age, y (IQR) |
21 (19–24) |
| Sex | |
| M | 29 (66) |
| F |
15 (34) |
| Race and ethnicity | |
| Asian, non-Hispanic | 12 (27) |
| White, non-Hispanic | 3 (7) |
| Other/unknown |
29 (66) |
| University affiliation | |
| Student | 43 (98) |
| Staff |
1 (2) |
| Case interview response type | |
| Telephone interview and electronic survey | 20 (45) |
| Electronic survey only | 13 (30) |
| Lost to follow-up |
11 (25) |
| University clinic visit <7 d of illness onset† | |
| Y | 8 (18) |
| N |
36 (82) |
| Symptom status | |
| No symptoms | 8 (18) |
| Unknown | 10 (23) |
| Any COVID-19 symptom | 26 (59) |
| Sore throat | 18 (41) |
| Cough | 16 (36) |
| Runny nose, cold-like symptoms | 16 (36) |
| Fever | 15 (34) |
| Muscle aches | 11 (25) |
| Fatigue | 10 (23) |
| Chills | 4 (9) |
| Headache | 4 (9) |
| Shortness of breath | 2 (5) |
| Difficulty breathing | 2 (5) |
| New loss of taste or smell | 2 (5) |
| Diarrhea | 2 (5) |
| Vomiting |
1 (2) |
| Outcome | |
| Hospitalized | 0 |
| Died |
0 |
| COVID-19 vaccination status | |
| Primary series completed, not boosted | 24 (55) |
| mRNA, Pfizer or Moderna | 16 (50) |
| Janssen/Johnson & Johnson | 5 (16) |
| Vaxzevria, Oxford-AstraZeneca | 11 (34) |
| Primary series and booster completed | 8 (18) |
| Unknown or unvaccinated |
12 (27) |
| Median days from primary vaccination series completion to illness onset (IQR)‡ | 216 (164–269) |
| Median days from booster vaccine dose to illness onset (IQR) | 27 (19–42) |
*Illness onset is defined as the first day of symptom onset or the day of positive specimen collection (if asymptomatic or lost to follow-up). IQR, interquartile range. †Within 7 days before or 7 days after illness onset. ‡Excludes case-patients who received a booster dose of COVID-19 vaccine (n = 8).
Page created: April 28, 2022
Page updated: June 18, 2022
Page reviewed: June 18, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.